ArticleNPJ vaccines2025
mRNA-1010 influenza vaccine elicits distinct and enhanced humoral immunity compared to adjuvanted inactivated vaccines.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05397223 (Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults
Who cites it
4 citing papers in PubMed.
- Article
- mRNA-1010 and the Future of Seasonal Influenza Prevention: Towards Next-Generation Respiratory Vaccination.Vaccines · 2026Article
- mRNA-based seasonal influenza vaccines: an overview of immunogenicity, efficacy, and safety.Frontiers in immunology · 2026Review
- Fc effector functions in RNA viral infections: mechanisms of antiviral immunity and implications for vaccine design.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Causing approximately a billion infections globally annually, the influenza virus represents one of the globe's greatest viral threats. While current vaccines protect against severe outcomes, especially for vulnerable populations, they offer limited prevention of infection and disease. Novel platforms like mRNA enable rapid updates, multivalent designs, and potentially stronger and more effective immune responses. To assess immune responses to mRNA vaccination, a system serology approach compared humoral profiles between recipients of investigational seasonal influenza mRNA-1010 vaccine and adjuvanted inactivated influenza vaccine (ClinicalTrials.gov Identifier: NCT05397223 ; registered May 31, 2022). Both platforms induced similar overall HA-specific antibody subclass and isotype responses. However, mRNA-1010 generated stronger Fc-receptor engaging antibodies, faster and completed functional humoral maturation, broader HA-specific binding antibodies, enhanced NK cell activating antibodies to two of the vaccine antigens, and higher HA-specific neutrophil activating antibodies across all vaccine HA antigens. Findings suggest that mRNA vaccination may elicit distinct Fab and Fc responses that may improve viral control and clearance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.